Trial Profile
A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Ferrous sulfate
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors American Regent; Luitpold Pharmaceuticals
- 26 Jun 2014 New trial record